vs

Side-by-side financial comparison of Avidity Biosciences, Inc. (RNA) and TAYLOR DEVICES, INC. (TAYD). Click either name above to swap in a different company.

Avidity Biosciences, Inc. is the larger business by last-quarter revenue ($12.5M vs $11.6M, roughly 1.1× TAYLOR DEVICES, INC.). TAYLOR DEVICES, INC. runs the higher net margin — 17.3% vs -1398.3%, a 1415.6% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 35.7%). TAYLOR DEVICES, INC. produced more free cash flow last quarter ($4.4M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs -2.7%).

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

Taylor Corporation is a privately owned print and communications company headquartered in North Mankato, Minnesota, and was founded in 1975 by businessman Glen Taylor. The company comprises more than 90 locations and employs nearly 10,000 employees. Taylor has print operations in dozens of U.S. states and multiple countries around the world.

RNA vs TAYD — Head-to-Head

Bigger by revenue
RNA
RNA
1.1× larger
RNA
$12.5M
$11.6M
TAYD
Growing faster (revenue YoY)
RNA
RNA
+398.3% gap
RNA
434.0%
35.7%
TAYD
Higher net margin
TAYD
TAYD
1415.6% more per $
TAYD
17.3%
-1398.3%
RNA
More free cash flow
TAYD
TAYD
$161.3M more FCF
TAYD
$4.4M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
-2.7%
TAYD

Income Statement — Q3 FY2025 vs Q2 FY2026

Metric
RNA
RNA
TAYD
TAYD
Revenue
$12.5M
$11.6M
Net Profit
$-174.4M
$2.0M
Gross Margin
47.0%
Operating Margin
-1513.5%
19.2%
Net Margin
-1398.3%
17.3%
Revenue YoY
434.0%
35.7%
Net Profit YoY
-117.0%
90.2%
EPS (diluted)
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RNA
RNA
TAYD
TAYD
Q4 25
$11.6M
Q3 25
$12.5M
$9.9M
Q2 25
$3.8M
$15.6M
Q1 25
$1.6M
$10.6M
Q4 24
$3.0M
$8.5M
Q3 24
$2.3M
$11.6M
Q2 24
$2.0M
$12.1M
Q1 24
$3.5M
$12.3M
Net Profit
RNA
RNA
TAYD
TAYD
Q4 25
$2.0M
Q3 25
$-174.4M
$2.2M
Q2 25
$-157.3M
$3.7M
Q1 25
$-115.8M
$2.0M
Q4 24
$-102.3M
$1.1M
Q3 24
$-80.4M
$2.7M
Q2 24
$-70.8M
$2.5M
Q1 24
$-68.9M
$2.7M
Gross Margin
RNA
RNA
TAYD
TAYD
Q4 25
47.0%
Q3 25
44.8%
Q2 25
48.6%
Q1 25
42.9%
Q4 24
45.5%
Q3 24
47.4%
Q2 24
48.8%
Q1 24
46.9%
Operating Margin
RNA
RNA
TAYD
TAYD
Q4 25
19.2%
Q3 25
-1513.5%
22.6%
Q2 25
-4448.7%
24.2%
Q1 25
-8360.9%
19.1%
Q4 24
-4069.6%
11.0%
Q3 24
-4200.9%
25.0%
Q2 24
-4040.4%
20.8%
Q1 24
-2178.6%
24.4%
Net Margin
RNA
RNA
TAYD
TAYD
Q4 25
17.3%
Q3 25
-1398.3%
22.1%
Q2 25
-4089.3%
23.7%
Q1 25
-7360.0%
19.0%
Q4 24
-3439.5%
12.4%
Q3 24
-3441.7%
23.0%
Q2 24
-3461.8%
20.5%
Q1 24
-1943.4%
22.0%
EPS (diluted)
RNA
RNA
TAYD
TAYD
Q4 25
Q3 25
$-1.27
Q2 25
$-1.21
Q1 25
$-0.90
Q4 24
$-0.80
Q3 24
$-0.65
Q2 24
$-0.65
Q1 24
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RNA
RNA
TAYD
TAYD
Cash + ST InvestmentsLiquidity on hand
$350.2M
$40.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.9B
$67.1M
Total Assets
$2.1B
$72.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RNA
RNA
TAYD
TAYD
Q4 25
$40.7M
Q3 25
$350.2M
$36.3M
Q2 25
$243.9M
$36.0M
Q1 25
$254.2M
$35.4M
Q4 24
$219.9M
$26.6M
Q3 24
$370.2M
$27.1M
Q2 24
$575.8M
$31.0M
Q1 24
$471.4M
$24.6M
Stockholders' Equity
RNA
RNA
TAYD
TAYD
Q4 25
$67.1M
Q3 25
$1.9B
$64.3M
Q2 25
$1.2B
$62.0M
Q1 25
$1.3B
$57.8M
Q4 24
$1.4B
$55.8M
Q3 24
$1.5B
$53.9M
Q2 24
$1.2B
$51.2M
Q1 24
$830.9M
$47.8M
Total Assets
RNA
RNA
TAYD
TAYD
Q4 25
$72.8M
Q3 25
$2.1B
$70.3M
Q2 25
$1.4B
$71.6M
Q1 25
$1.5B
$70.1M
Q4 24
$1.6B
$62.9M
Q3 24
$1.6B
$61.9M
Q2 24
$1.3B
$63.1M
Q1 24
$951.5M
$54.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RNA
RNA
TAYD
TAYD
Operating Cash FlowLast quarter
$-156.2M
$5.7M
Free Cash FlowOCF − Capex
$-156.9M
$4.4M
FCF MarginFCF / Revenue
-1257.6%
38.3%
Capex IntensityCapex / Revenue
5.7%
11.3%
Cash ConversionOCF / Net Profit
2.86×
TTM Free Cash FlowTrailing 4 quarters
$-592.3M
$14.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RNA
RNA
TAYD
TAYD
Q4 25
$5.7M
Q3 25
$-156.2M
$483.6K
Q2 25
$-199.7M
$1.9M
Q1 25
$-124.8M
$9.0M
Q4 24
$-99.9M
$103.1K
Q3 24
$-65.6M
$-3.6M
Q2 24
$-65.0M
$6.5M
Q1 24
$-70.4M
$-685.0K
Free Cash Flow
RNA
RNA
TAYD
TAYD
Q4 25
$4.4M
Q3 25
$-156.9M
$298.6K
Q2 25
$-203.0M
$491.3K
Q1 25
$-128.6M
$8.8M
Q4 24
$-103.8M
$-620.5K
Q3 24
$-67.3M
$-3.8M
Q2 24
$-65.5M
$6.1M
Q1 24
$-71.3M
$-895.5K
FCF Margin
RNA
RNA
TAYD
TAYD
Q4 25
38.3%
Q3 25
-1257.6%
3.0%
Q2 25
-5277.1%
3.2%
Q1 25
-8174.3%
83.6%
Q4 24
-3491.0%
-7.3%
Q3 24
-2881.8%
-33.0%
Q2 24
-3204.6%
51.0%
Q1 24
-2012.3%
-7.3%
Capex Intensity
RNA
RNA
TAYD
TAYD
Q4 25
11.3%
Q3 25
5.7%
1.9%
Q2 25
86.9%
9.3%
Q1 25
238.6%
1.8%
Q4 24
131.7%
8.5%
Q3 24
72.9%
2.1%
Q2 24
26.0%
3.3%
Q1 24
25.8%
1.7%
Cash Conversion
RNA
RNA
TAYD
TAYD
Q4 25
2.86×
Q3 25
0.22×
Q2 25
0.52×
Q1 25
4.51×
Q4 24
0.10×
Q3 24
-1.35×
Q2 24
2.65×
Q1 24
-0.25×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons